Tirzepatide
SURPASS-T1D-1
Eli Lilly · Phase 3 · Active, not recruiting · Enrollment 905
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Tirzepatide Dose 1 | Obesity + T2D | n/r | 49 | n/r | n/r |
| Tirzepatide Dose 2 | Obesity + T2D | n/r | 49 | n/r | n/r |
| Tirzepatide Dose 3 | Obesity + T2D | n/r | 49 | n/r | n/r |
| Tirzepatide Dose 4 | Obesity + T2D | n/r | 49 | n/r | n/r |
| Placebo | Obesity + T2D | n/r | 49 | n/r | n/r |